{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:38Z","timestamp":1792511618403,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["PCTR-16-383171"],"award-info":[{"award-number":["PCTR-16-383171"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["21040501.03"],"award-info":[{"award-number":["21040501.03"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer\u2019s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) subtypes to reduce dose-limiting side-effects that have been the hallmark of earlier orthosteric mAChR agonists. VU0467319 (VU319) is an investigational positive allosteric modulator of the M\n                    <jats:sub>1<\/jats:sub>\n                    mAChR. A Phase 1 first-in-human study was conducted assessing safety and brain activity utilizing cognitive tasks and event-related potentials (ERPs) in single-ascending dose and food effect studies. VU319 was given orally to 52 healthy volunteers aged 18\u201355 years. The single ascending dose study tested 40 participants in five dose escalating cohorts (60, 120, 240, 400, 600\u00a0mg; 6 VU319\/2 placebo per dose). The food effect study involved 12 participants, 10 VU319 (120\u00a0mg)\/2 placebo. Exploratory cognitive and electrophysiological tasks were examined pre-dosing and at 5\u00a0h post-dose. Tolerability was good with no observed dose limiting side effects throughout the full dose range tested. In the single ascending dose study, there were 47 TEAEs reported across the 5 cohorts, 14 in the placebo group and 33 across the 5 active dose cohorts. In the food effect study, there were 20 TEAEs reported, 6 in the placebo group and 14 in the fed and fasted conditions. Drug exposure increased with dose in a less than dose-proportional manner with a half-life ranging from 30 to 55\u00a0h. Peak concentration was observed between 5 and 9.5\u00a0h across the dosage groups. Absorption was increased with food. Exploratory cognitive\/ERP testing showed evidence for drug-induced CNS activity on higher doses of VU319 compared to placebo. Single dose VU319 across five ascending cohorts appeared to have a favorable safety profile and a PK profile consistent with once daily dosing. Target engagement results suggest stimulation of the cholinergic system functioning in healthy adults following a single dose of VU319. These results provide a strong foundation for further studies of positive allosteric modulators of muscarinic M\n                    <jats:sub>1<\/jats:sub>\n                    receptors for potential cognitive or behavioral benefits.\n                  <\/jats:p>","DOI":"10.1186\/s13195-025-01798-4","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:10:35Z","timestamp":1751350235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer\u2019s disease: a single ascending-dose study in healthy participants"],"prefix":"10.1186","volume":"17","author":[{"given":"Alexander C.","family":"Conley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Key","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer U.","family":"Blackford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bubser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerri M.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"1798_CR1","first-page":"3","volume":"64","author":"GT Grossberg","year":"2003","unstructured":"Grossberg GT. Diagnosis and treatment of alzheimer\u2019s disease. J Clin Psychiatry. 2003;64:3\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1798_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1798_CR3","doi-asserted-by":"crossref","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain [Internet]. 2023 Nov 1 [cited 2025 Feb 11];146(11):4414. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10629981\/","DOI":"10.1093\/brain\/awad188"},{"key":"1798_CR4","doi-asserted-by":"crossref","unstructured":"Beveridge J, Kaniecki E, Naidu A, Silverglate BD, Grossberg G. How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early Alzheimer\u2019s disease? Expert Opin Emerg Drugs [Internet]. 2024 [cited 2025 Feb 11];29(1):35\u201343. Available from: https:\/\/www.tandfonline.com\/action\/journalInformation?journalCode=iemd20","DOI":"10.1080\/14728214.2024.2304059"},{"issue":"2","key":"1798_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.pbb.2011.02.022","volume":"99","author":"JA Dumas","year":"2011","unstructured":"Dumas JA, Newhouse PA. The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav. 2011;99(2):254\u201361.","journal-title":"Pharmacol Biochem Behav"},{"key":"1798_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408\u201314.","journal-title":"Science"},{"key":"1798_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","volume":"68","author":"DS Auld","year":"2002","unstructured":"Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer\u2019s disease and the basal forebrain cholinergic system: relations to \u03b2-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209\u201345.","journal-title":"Prog Neurobiol"},{"key":"1798_CR8","doi-asserted-by":"crossref","unstructured":"Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Sci (1979). 1982;215:1237\u20139.","DOI":"10.1126\/science.7058341"},{"key":"1798_CR9","doi-asserted-by":"crossref","unstructured":"Vega JN, Newhouse PA. Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments. Curr Psychiatry Rep. 2014;16(10).","DOI":"10.1007\/s11920-014-0490-8"},{"key":"1798_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"MB Colovic","year":"2013","unstructured":"Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol. 2013;11:315\u201335.","journal-title":"Curr Neuropharmacol"},{"key":"1798_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","volume":"32","author":"WJ Deardorff","year":"2015","unstructured":"Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of alzheimer\u2019s disease. Drugs Aging. 2015;32:537\u201347.","journal-title":"Drugs Aging"},{"issue":"10","key":"1798_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/13543784.2016.1216972","volume":"25","author":"D Galimberti","year":"2016","unstructured":"Galimberti D, Scarpini E. Old and new acetylcholinesterase inhibitors for alzheimer\u2019s disease. Expert Opin Investig Drugs. 2016;25(10):1181\u20137.","journal-title":"Expert Opin Investig Drugs"},{"key":"1798_CR13","first-page":"183","volume":"10","author":"DJ Foster","year":"2014","unstructured":"Foster DJ, Choi DL, Jeffrey Conn P, Rook JM. Activation of M 1 and M 4 muscarinic receptors as potential treatments for alzheimer\u2019s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183\u201391.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1798_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","volume":"18","author":"BJ Melancon","year":"2013","unstructured":"Melancon BJ, Tarr JC, Panarese JD, Wood MR, Lindsley CW. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and alzheimer\u2019s disease. Drug Discov Today. 2013;18:1185\u201399.","journal-title":"Drug Discov Today"},{"key":"1798_CR15","doi-asserted-by":"crossref","unstructured":"Buckley NJ, Burnstock G. Autoradiographic localization of peripheral M1 muscarinic receptors using [3H]pirenzepine. Brain Res [Internet]. 1986 Jun 4 [cited 2025 May 4];375(1):83\u201391. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/0006899386909613","DOI":"10.1016\/0006-8993(86)90961-3"},{"key":"1798_CR16","doi-asserted-by":"crossref","unstructured":"Jiang S, Li Y, Zhang C, Zhao Y, Bu G, Xu H et al. M1 muscarinic acetylcholine receptor in Alzheimer\u2019s disease. Neurosci Bull [Internet]. 2014 Mar 3 [cited 2025 May 4];30(2):295\u2013307. Available from: https:\/\/link.springer.com\/article\/10.1007\/s12264-013-1406-z","DOI":"10.1007\/s12264-013-1406-z"},{"key":"1798_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nn992","volume":"6","author":"SG Anagnostaras","year":"2003","unstructured":"Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci. 2003;6:51\u20138.","journal-title":"Nat Neurosci"},{"key":"1798_CR18","doi-asserted-by":"publisher","first-page":"14271","DOI":"10.1523\/JNEUROSCI.3930-09.2009","volume":"29","author":"JK Shirey","year":"2009","unstructured":"Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009;29:14271\u201386.","journal-title":"J Neurosci"},{"issue":"3","key":"1798_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","volume":"30","author":"PJ Conn","year":"2009","unstructured":"Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009;30(3):148\u201355.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"1798_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/00002018-199819060-00004","volume":"19","author":"A Nordberg","year":"1998","unstructured":"Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of alzheimer\u2019s disease. A comparison of tolerability and Pharmacology. Drug Saf. 1998;19(6):465\u201380.","journal-title":"Drug Saf"},{"key":"1798_CR21","doi-asserted-by":"crossref","unstructured":"Torjesen I, Schizophrenia. US approves first new treatment in decades. BMJ [Internet]. 2024 Sep 30 [cited 2025 Jan 16];386:q2133. Available from: https:\/\/www.bmj.com\/content\/386\/bmj.q2133","DOI":"10.1136\/bmj.q2133"},{"key":"1798_CR22","doi-asserted-by":"publisher","unstructured":"Mills J. A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy). Issues Ment Health Nurs [Internet]. 2024 [cited 2025 Jan 16];45:1364\u20137. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/01612840.2024.2427561","DOI":"10.1080\/01612840.2024.2427561"},{"issue":"10","key":"1798_CR23","first-page":"9","volume":"20","author":"AC Conley","year":"2018","unstructured":"Conley AC, Newhouse PA. Advances in drug discovery and development in geriatric psychiatry. Curr Psychiatry Rep. 2018;20(10):9.","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"1798_CR24","first-page":"692","volume":"13","author":"PJ Conn","year":"2014","unstructured":"Conn PJ, Lindsley CW, Meiler J, Niswender CM. Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Publishing Group. 2014;13(9):692\u2013708.","journal-title":"Nat Publishing Group"},{"key":"1798_CR25","doi-asserted-by":"publisher","unstructured":"Poslunsey MS, Wood MR, Han C, Stauffer SR, Panarese JD, Melancon BJ et al. Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials. ACS Chem Neurosci [Internet]. 2024 [cited 2025 Jan 21];16:95\u2013107. Available from: https:\/\/doi.org\/10.1021\/acschemneuro.4c00769","DOI":"10.1021\/acschemneuro.4c00769"},{"key":"1798_CR26","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/npp.2015.189","volume":"41","author":"A Ghoshal","year":"2016","unstructured":"Ghoshal A, Rook JM, Dickerson JW, Roop GN, Morrison RD, Jalan-Sakrikar N, et al. Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology. 2016;41:598\u2013610.","journal-title":"Neuropsychopharmacology"},{"key":"1798_CR27","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1021\/acschemneuro.5b00123","volume":"6","author":"RW Gould","year":"2015","unstructured":"Gould RW, Dencker D, Grannan M, Bubser M, Zhan X, Wess J, et al. Role for the M1 muscarinic acetylcholine receptor in Top-Down cognitive processing using a touchscreen visual discrimination task in mice. ACS Chem Neurosci. 2015;6:1683\u201395.","journal-title":"ACS Chem Neurosci"},{"key":"1798_CR28","doi-asserted-by":"crossref","unstructured":"Ma L, Seager M, Wittmann M, Jacobson M, Bickel D, Burno M, S A [Internet]. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U. 2009 Sep 15 [cited 2025 Apr 28];106(37):15950\u20135. Available from: https:\/\/doi.org\/10.1073\/pnas.0900903106?download","DOI":"10.1073\/pnas.0900903106"},{"key":"1798_CR29","doi-asserted-by":"crossref","unstructured":"Omura GA. Modified Fibonacci search. J Clin Oncol [Internet]. 2003 Aug 1 [cited 2025 Mar 8];21(16):3177\u20133177. Available from: https:\/\/europepmc.org\/article\/med\/12915613","DOI":"10.1200\/JCO.2003.99.058"},{"issue":"4","key":"1798_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/arclin\/4.4.351","volume":"4","author":"T Kupke","year":"1989","unstructured":"Kupke T, Lewis R. Relative influence of subject variables and neurological parameters on neuropsychological performance of adult seizure patients. Arch Clin Neuropsychol. 1989;4(4):351\u201363.","journal-title":"Arch Clin Neuropsychol"},{"key":"1798_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/978-3-642-69659-6_4","volume":"1","author":"I Hindmarch","year":"1984","unstructured":"Hindmarch I. Psychological performance models as indicators of the effects of hypnotic drugs on sleep. Psychopharmacol Suppl. 1984;1:58\u201368.","journal-title":"Psychopharmacol Suppl"},{"key":"1798_CR32","first-page":"175","volume":"29","author":"CK Conners","year":"2000","unstructured":"Conners CK, Staff MHS, Connelly V, Campbell S, MacLean M, Barnes J. Conners\u2019 continuous performance test II (CPT II V. 5). Multi-Health Syst Inc. 2000;29:175\u201396.","journal-title":"Multi-Health Syst Inc"},{"issue":"1","key":"1798_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/00335558008248231","volume":"32","author":"MI Posner","year":"1980","unstructured":"Posner MI. Orienting of attention. Q J Experimental Psychol. 1980;32(1):3\u201325.","journal-title":"Q J Experimental Psychol"},{"issue":"4","key":"1798_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1162\/jocn.1997.9.4.462","volume":"9","author":"J Jonides","year":"1997","unstructured":"Jonides J, Schumacher EH, Smith EE, Lauber EJ, Awh E, Minoshima S, et al. Verbal working memory load affects regional brain activation as measured by PET. J Cogn Neurosci. 1997;9(4):462\u201375.","journal-title":"J Cogn Neurosci"},{"key":"1798_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1093\/brain\/awh177","volume":"127","author":"AJ Saykin","year":"2004","unstructured":"Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004;127:1574\u201383.","journal-title":"Brain"},{"issue":"November","key":"1798_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1212\/WNL.24.11.1019","volume":"24","author":"H Buschke","year":"1974","unstructured":"Buschke H, Fuld PA. Evaluating storage,retention, and retrieval in disordered memory and learning. Neurology. 1974;24(November):1019\u201325.","journal-title":"Neurology"},{"issue":"4","key":"1798_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF01186911","volume":"8","author":"R Srinivasan","year":"1996","unstructured":"Srinivasan R, Nunez PL, Tucker DM, Silberstein RB, Cadusch PJ. Spatial sampling and filtering of EEG with spline laplacians to estimate cortical potentials. Brain Topogr. 1996;8(4):355\u201366.","journal-title":"Brain Topogr"},{"issue":"1","key":"1798_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neurobiolaging.2013.07.024","volume":"35","author":"AP Key","year":"2014","unstructured":"Key AP, Dykens EM. Event-related potential index of age-related differences in memory processes in adults with down syndrome. Neurobiol Aging. 2014;35(1):247\u201353.","journal-title":"Neurobiol Aging"},{"key":"1798_CR39","doi-asserted-by":"crossref","unstructured":"Comerchero MD, Polich J. P3a and P3b from typical auditory and visual stimuli. 1999;110:24\u201330.","DOI":"10.1016\/S0168-5597(98)00033-1"},{"key":"1798_CR40","doi-asserted-by":"crossref","unstructured":"Polich J. Updating P300: An integrative theory of P3a and P3b. Clinical Neurophysiology [Internet]. 2007;118(10):2128\u201348. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388245707001897","DOI":"10.1016\/j.clinph.2007.04.019"},{"issue":"6","key":"1798_CR41","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1388-2457(99)00044-9","volume":"110","author":"M Jungh\u00f6fer","year":"1999","unstructured":"Jungh\u00f6fer M, Elbert T, Tucker DM, Braun C. The Polar average reference effect: A bias in estimating the head surface integral in EEG recording. Clin Neurophysiol. 1999;110(6):1149\u201355.","journal-title":"Clin Neurophysiol"},{"issue":"7","key":"1798_CR42","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1109\/10.686789","volume":"45","author":"R Srinivasan","year":"1998","unstructured":"Srinivasan R, Nunez PL, Silberstein RB. Spatial filtering and neocortical dynamics: estimates of EEG coherence. IEEE Trans Biomed Eng. 1998;45(7):814\u201326.","journal-title":"IEEE Trans Biomed Eng"},{"key":"1798_CR43","doi-asserted-by":"crossref","unstructured":"Okour M, Brundage RC. Modeling Enterohepatic Circulation. Curr Pharmacol Rep [Internet]. 2017 Oct 1 [cited 2025 Feb 12];3(5):301\u201313. Available from: https:\/\/link.springer.com\/article\/10.1007\/s40495-017-0096-z","DOI":"10.1007\/s40495-017-0096-z"},{"issue":"1","key":"1798_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.brainresrev.2004.08.006","volume":"48","author":"M Sarter","year":"2005","unstructured":"Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev. 2005;48(1):98\u2013111.","journal-title":"Brain Res Rev"},{"key":"1798_CR45","doi-asserted-by":"crossref","unstructured":"Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci [Internet]. 1993 [cited 2022 Mar 14];52(5\u20136):441\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8441326\/","DOI":"10.1016\/0024-3205(93)90300-R"},{"key":"1798_CR46","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1523\/JNEUROSCI.15-05-04077.1995","volume":"15","author":"AI Levey","year":"1995","unstructured":"Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci. 1995;15:4077\u201392.","journal-title":"J Neurosci"},{"issue":"10","key":"1798_CR47","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1523\/JNEUROSCI.11-10-03218.1991","volume":"11","author":"AI Levey","year":"1991","unstructured":"Levey AI, Kitt Ca, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991;11(10):3218\u201326.","journal-title":"J Neurosci"},{"key":"1798_CR48","doi-asserted-by":"crossref","unstructured":"Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T et al. An Acetylcholine M1 Receptor\u2013Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial. JAMA Neurol [Internet]. 2025 Jan 6 [cited 2025 Jan 16]; Available from: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2828334","DOI":"10.1001\/jamaneurol.2024.4519"},{"key":"1798_CR49","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95.","DOI":"10.1016\/j.jbi.2019.103208"},{"issue":"2","key":"1798_CR50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381.","journal-title":"J Biomed Inf"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01798-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T06:10:39Z","timestamp":1751350239000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01798-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1798"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01798-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6271510\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Duke University Institutional Review Board and was performed in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. All participants signed written informed consent documents before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Vanderbilt University and the Warren Center for Neuroscience Drug Discovery are partnered with Acadia Pharmaceuticals to develop next generation M1 PAMs and hold patents to the same. The other authors have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}